{"DataElement":{"publicId":"5782321","version":"2","preferredName":"Crizotinib Agent Day Treatment on Hold Count","preferredDefinition":"Information related to the number of days Crizotinib is held.","longName":"CRZB_AGT_DY_THPY_HLD_CT","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5733001","version":"1","preferredName":"Crizotinib Agent Day Treatment on Hold","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._A treatment is suspended.","longName":"5731690v1.0:5732999v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"5731690","version":"1","preferredName":"Crizotinib Agent","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C74061:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C213504-F0E4-65FC-E053-F662850A793C","latestVersionIndicator":"Yes","beginDate":"2017-04-01","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-01","modifiedBy":"ONEDATA","dateModified":"2017-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5732999","version":"1","preferredName":"Day Treatment on Hold","preferredDefinition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.:A treatment is suspended.","longName":"C25301:C106470","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Treatment on Hold","conceptCode":"C106470","definition":"A treatment is suspended.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C5D987A-C5CC-2B18-E053-F662850A4B6E","latestVersionIndicator":"Yes","beginDate":"2017-04-04","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-04","modifiedBy":"ONEDATA","dateModified":"2017-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C5D987A-C5DD-2B18-E053-F662850A4B6E","latestVersionIndicator":"Yes","beginDate":"2017-04-04","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-04","modifiedBy":"MAESKEB","dateModified":"2018-11-21","changeDescription":"Workflow and Registration Status Changed per Brenda Duggan; 05.16.18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5778091","version":"1.1","preferredName":"Day Count","preferredDefinition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day._To determine the number or amount of something; the result of this activity.","longName":"5778091v1.0","context":"COG","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2207941","version":"1","preferredName":"Day Count","preferredDefinition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours.:To determine the number or amount of something; the result of this activity.","longName":"C25301:C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-35FE-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B31C6DB-5FE9-3D60-E053-F662850AA878","latestVersionIndicator":"Yes","beginDate":"2017-04-19","endDate":null,"createdBy":"MAESKEB","dateCreated":"2018-11-21","modifiedBy":"MAESKEB","dateModified":"2019-08-27","changeDescription":"Versioned VD to add max length 11/21/18 bsm","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Number of day(s) Crizotinib w","type":"Preferred Question Text","description":"Number of day(s) Crizotinib was held:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7B2F635E-D2AE-65F3-E053-F662850A4E0F","latestVersionIndicator":"Yes","beginDate":"2017-04-26","endDate":null,"createdBy":"MAESKEB","dateCreated":"2018-11-21","modifiedBy":"MAESKEB","dateModified":"2018-11-21","changeDescription":"Workflow and Registration Status changes per Brenda Duggan; 05.16.18; versioned CDE to use versioned VD 11/21/18 bsm.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}